AR055203A1 - Derivados de benzotiofeno con propiedades antipsicoticas - Google Patents
Derivados de benzotiofeno con propiedades antipsicoticasInfo
- Publication number
- AR055203A1 AR055203A1 ARP060103780A ARP060103780A AR055203A1 AR 055203 A1 AR055203 A1 AR 055203A1 AR P060103780 A ARP060103780 A AR P060103780A AR P060103780 A ARP060103780 A AR P060103780A AR 055203 A1 AR055203 A1 AR 055203A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- substituent
- lower alkyl
- alkyl group
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 53
- 125000001424 substituent group Chemical group 0.000 abstract 22
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 11
- -1 tetrahydroquinoxalinyl group Chemical group 0.000 abstract 10
- 125000002252 acyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000004043 oxo group Chemical group O=* 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000003435 aroyl group Chemical group 0.000 abstract 3
- 125000002541 furyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000002883 imidazolyl group Chemical group 0.000 abstract 3
- 125000001041 indolyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000005242 carbamoyl alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000005936 piperidyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005019 carboxyalkenyl group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 abstract 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 abstract 1
- 125000005435 dihydrobenzoxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 abstract 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 abstract 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000006542 morpholinylalkyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000004963 sulfonylalkyl group Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
El compuesto de la presente posee un amplio espectro de tratamiento para desordenes mentales que incluyen desordenes del sistema nervioso central, ningun efecto colateral y elevada seguridad. Reivindicacion 1: Un compuesto heterocíclico o una sal del mismo representado por la formula [1], donde R2 representa un átomo de hidrogeno o un alquilo inferior; A representa un grupo alquileno inferior o un grupo alquenileno inferior; y R1 representa un grupo aromático o un grupo heterocíclico seleccionado del grupo que consiste de (I) a (IV) a continuacion: (I) un grupo cicloalquilo C3-8; (II) un grupo aromático seleccionado de un grupo fenilo, un grupo naftilo, un grupo dihidroindenilo y un grupo tetrahidronaftilo; (III) un grupo heteromonocíclico saturado o no saturado que posee 1 a 4 heteroátomos seleccionado del grupo que consiste de un átomo de nitrogeno, un átomo de oxígeno y un átomo de azufre; y (IV) un grupo heterocíclico fusionado a benceno que posee 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de nitrogeno, un átomo de oxígeno y un átomo de azufre y es seleccionado del grupo que consiste de (1) un grupo tetrahidroquinoxalinilo, (2) un grupo tetrahidroquinazolinilo, (3) un grupo dihidroquinazolinilo, (4) un grupo indolinilo, (5) un grupo indolilo, (6) un grupo isoindolinilo, (7) un grupo benzimidazolinilo, (8) un grupo dihidrobenzimidazolinilo, (9) un grupo tetrahidrobenzoazepinilo, (10) un grupo tetrahidrobenzodiazepinilo, (11) un grupo hexahidrobenzazocinilo, (12) un grupo dihidrobenzoxazinilo, (13) un grupo dihidrobenzoxazolilo, (14) un grupo benzisoxazolilo, (15) un grupo benzoxadiazolilo, (16) un grupo tetrahidrobenzoxazepinilo, (17) un grupo dihidrobenzotiazinilo, (18) un grupo benzotiazolilo, (19) un grupo benzoxatiolilo, (20) un grupo cromenilo, (21) un grupo dihidrobenzofurilo, (22) un grupo carbazolilo, (23) un grupo dibenzofurilo y (24) un grupo quinoxalinilo en donde por lo menos un grupo seleccionado del grupo que consiste de los grupos (1) al (66) a continuacion puede estar presente como substituyente en el grupo cicloalquilo C3-8, el grupo aromático y el grupo heterocíclico representado por R1: (1) un grupo alquilo inferior, (2) un grupo alquenilo inferior, (3) un grupo alquilo inferior substituido por halogeno, (4) un grupo alcoxilo inferior, (5) un grupo ariloxilo inferior, (6) un grupo alquiltio inferior, (7) un grupo alcoxilo inferior substituido por halogeno, (8) un grupo hidroxilo, (9) un grupo hidroxilo protegido, (10) un grupo hidroxialquilo inferior, (11) un grupo hidroxialquilo inferior protegido, (12) un átomo de halogeno, (13) un grupo ciano, (14) un grupo arilo, (15) un grupo nitro, (16) un grupo amino, (17) un grupo amino que tiene un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcanoilo inferior, un grupo alcoxicarbonilo inferior, un grupo alquilsulfonilo inferior, un grupo aminocarbamoilo inferior, un grupo carbamoilalquilo inferior, un grupo alcanoilamino inferior, un grupo alcanoilo inferior alcanoilamino inferior y alcanoilo inferior carbonilaminoalcoxilo inferior como substituyente, (18) un grupo alcanoiloinferior, (19) un grupo arilsulfonilo que puede tener un grupo alquilo inferior en el grupo arilo group, (20) un grupo carboxilo, (21) un grupo alcoxicarbonilo inferior, (22) un grupo carboxialquilo inferior, (23) un grupo alquilo inferior alcoxicarbonilo inferior, (24) un grupo alcanoilo inferior alcanoilamino inferior, (25) un grupo carboxialquenilo inferior, (26) un grupo alquenilo inferior alcoxicarbonilo inferior, (27) un grupo carbamoilalquenilo inferior que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior y un grupo alquilo inferior substituido por halogeno como substituyente, (28) un grupo carbamoilo que puede tener un grupo seleccionado del grupo que consiste de grupos (i) a (lxxviii) a continuacion como substituyente: (i) un grupo alquilo inferior, (ii) un grupo alcoxilo inferior, (iii) un grupo hidroxialquilo inferior, (iv) un grupo alcoxilo inferior alquilo inferior, (v) un grupo ariloxialquilo inferior, (vi) un grupo alquilo inferior substituido por halogeno, (vii) un grupo amino alquilo inferior que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcanoilo inferior, un grupo aroilo y un grupo carbamoilo group, (viii) un grupo cicloalquilo C3- 8 que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo, un grupo hidroxilo, un grupo alcoxicarbonilo inferior y un grupo fenilalcoxilo inferior como substituyente, (ix) un grupo cicloalquilo C3-8 substituido por un grupo alquilo inferior, (x) un grupo alquenilo inferior, (xi) un grupo carbamoilalquilo inferior que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo alquilo inferior, un grupo fenilo que puede tener grupo(s) alquilo inferior y grupo(s) fenilo que pueden tener grupo(s) alcoxilo inferior como substituyente, (xii) un grupo alquilo inferior alcoxicarbonilo inferior, (xiii) un grupo furilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente) en el grupo furilo, (xiv) un grupo tetrahidrofurilalquilo inferior, (xv) un grupo 1,3-dioxolanilalquilo inferior, (xvi) un grupo tetrahidropiranilalquilo inferior, (xvii) un grupo pirrolilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirrolilo), (xviii) un grupo alquilo inferior substitutido con un grupo dihidropirazolilo que puede tener grupo(s) oxo, (xix) un grupo pirazolilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirazolilo), (xx) un grupo imidazolilalquilo inferior, (xxi) un grupo piridilalquilo inferior, (xxii) un grupo pirazinilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirazinilo), (xxiii) un grupo pirrolidinilalquilo (que puede tener grupo(s) seleccionado(s) del grupo que consiste de grupo(s) oxo y un grupo alquilo inferior como substituyente en el grupo pirrolidinilo), (xxiv) un grupo piperidilalquilo inferior (que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo benzoilo y un grupo alcanoilo inferior como substituyente en el grupo piperidilo), (xxv) un grupo piperazinilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo piperazinilo), (xxvi) un grupo morfolinilalquilo inferior, (xxvii) un grupo tienilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo tienilo), (xxviii) un grupo tiazolilalquilo inferior, (xxix) un grupo dihidrobenzofurilalquilo inferior, (xxx) un grupo benzopiranilalquilo inferior (que puede tener grupo(s) oxo como substituyente en el grupo benzopiranilo), (xxxi) un grupo benzimidazolilalquilo inferior, (xxxii) un grupo indolilalquilo inferior (que puede tener grupo(s) alcoxicarbonilo inferior en el grupo alquilo), (xxxiii) un grupo imidazolilalquilo inferior que tiene substituyente(s) seleccionado(s) del grupo que consiste de un grupo carbamoilo group y un grupo alcoxicarbonilo inferior en el grupo alquilo, (xxxiv) un grupo piridilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxilo y un grupo alquilo inferior alquiltioinferior alquilo como un substituyente, (xxxv) un grupo pirrolidinilo que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxicarbonilo inferior, un grupo alcanoilo inferior y un grupo aroilo como un substituyente, (xxxvi) un grupo piperidilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxicarbonilo inferior, un grupo alcanoilo inferior y un grupo aroilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior y un átomo de halogeno como substituyente, (xxxvii) un grupo tetrahidrofurilo que puede tener grupo(s) oxo, (xxxviii) un grupo hexahidroazepinilo que puede tener grupo(s) oxo, (xxxix) un grupo pirazolilo que puede tener grupo(s) group (s) seleccionado(s) del grupo que consiste de un grupo alquilo, un grupo arilo y un grupo furilo como un substituyente, (xl) un grupo tiazolilo, (xli) un grupo tiadiazolilo que puede tener grupo(s) alquilo inferior, (xlii) un grupo isoxazolilo que puede tener grupo(s) alquilo inferior, (xliii) un grupo indazolilo, (xliv) un grupo indolilo, (xlv) un grupo tetrahidrobenzotiazolilo, (xlvi) un grupo tetrahidroquinolilo que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo alquilo inferior, un grupo alcoxiloinferior, un átomo de halogeno y un grupo oxo como un substituyente, (xlvii) un grupo quinolilo que puede tener grupo(s) alquilo inferior, (xlviii) un grupo benzodioxolilalquilo inferior, (xlix) un grupo arilo que puede tener grupo(s) como substituyente, seleccionado del grupo que consiste de un átomo de halogeno; un grupo alquilo inferior; un grupo alcoxiloinferior; un grupo alquilo inferior substituido por halogeno; un grupo alcoxilo inferior substituido por halogeno; un grupo alquenilo inferior; un grupo amino que puede tener un grupo seleccionado del grupo que consiste de un grupo alcanoilo inferior, un grupo sulfonilalquilo inferior, un grupo alquilo inferior y un grupo arilo; un grupo sulfamoilo; un grupo alquiltio inferior; un grupo alcanoilo inferior ; un grupo alcoxicarbonilo inferior; un grupo pirrolilo; un grupo alquinilo inferior; un grupo ciano; un grupo nitro; un grupo ariloxilo; un grupo arilalcoxilo inferior; un grupo hidroxilo; un grupo hidroxialquilo inferior; un grupo carbamoilo que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior y un grupo arilo; un grupo pirazolilo; un grupo pirrolidinilo que puede tener grupo(s) oxo; un grupo oxazolilo; un grupo imidazolilo que puede tener grupo(s) alquilo inferior; un grupo dihidrofurilo que puede tener grupo(s) oxo; un grupo tiazolidi
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005251055 | 2005-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055203A1 true AR055203A1 (es) | 2007-08-08 |
Family
ID=37709698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103780A AR055203A1 (es) | 2005-08-31 | 2006-08-30 | Derivados de benzotiofeno con propiedades antipsicoticas |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8071600B2 (es) |
| EP (4) | EP1919907B9 (es) |
| JP (1) | JP4785677B2 (es) |
| KR (2) | KR20100063807A (es) |
| CN (4) | CN102558140A (es) |
| AR (1) | AR055203A1 (es) |
| AT (4) | ATE499369T1 (es) |
| AU (2) | AU2006285607B2 (es) |
| BR (1) | BRPI0615140A2 (es) |
| CA (1) | CA2620688C (es) |
| CY (1) | CY1111671T1 (es) |
| DE (1) | DE602006020294D1 (es) |
| DK (1) | DK1919907T5 (es) |
| ES (4) | ES2382445T3 (es) |
| IL (1) | IL189383A (es) |
| MX (1) | MX2008002736A (es) |
| MY (1) | MY145670A (es) |
| PL (1) | PL1919907T3 (es) |
| PT (1) | PT1919907E (es) |
| RU (1) | RU2415854C2 (es) |
| SG (1) | SG155180A1 (es) |
| SI (1) | SI1919907T1 (es) |
| TW (1) | TWI329641B (es) |
| WO (1) | WO2007026959A2 (es) |
| ZA (1) | ZA200801888B (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06000795A (es) | 2003-07-22 | 2006-08-23 | Arena Pharm Inc | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo. |
| SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
| CA2649043C (en) * | 2006-04-19 | 2013-09-17 | Astellas Pharma Inc. | Azolecarboxamide derivative |
| CN104761498B (zh) | 2006-05-18 | 2017-12-26 | 艾尼纳制药公司 | 5‑ht2a血清素受体的调节剂 |
| EP2527329A1 (en) | 2006-05-18 | 2012-11-28 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor |
| US8148417B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| TWI329102B (en) * | 2006-08-15 | 2010-08-21 | Nat Health Research Institutes | Thiourea compounds and method for inhibiting hepatitis c virus infection |
| WO2008020306A2 (en) * | 2006-08-18 | 2008-02-21 | Pfizer Products Inc. | Isoindole derivatives |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| EP1972628A1 (en) * | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as CNS active compounds |
| WO2008124300A1 (en) * | 2007-04-10 | 2008-10-16 | National Health Research Institutes | Hepatitis c virus inhibitors |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| US7897764B2 (en) * | 2007-06-08 | 2011-03-01 | National Health Research Institutes | Thiourea derivatives |
| JP2010532382A (ja) * | 2007-06-29 | 2010-10-07 | エモリー・ユニバーシテイ | 神経保護のためのｎｍｄａ受容体拮抗薬 |
| US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| US20110251212A1 (en) * | 2007-08-21 | 2011-10-13 | Shionogi & Co., Ltd. | Piperazine derivatives |
| DK2206707T3 (da) | 2007-10-24 | 2014-08-11 | Astellas Pharma Inc | Azolcarboxamidforbindelse eller salt deraf |
| US8394960B2 (en) * | 2007-10-29 | 2013-03-12 | Merck Sharp & Dohme Corp. | Thiazole carboxamide derivatives and their use to treat cancer |
| WO2009101018A2 (en) * | 2008-02-15 | 2009-08-20 | F. Hoffmann-La Roche Ag | 3-alkyl-piperazine derivatives and uses thereof |
| PL2254873T3 (pl) | 2008-02-22 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek benzodiazepinowy i kompozycja farmaceutyczna |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US8198284B2 (en) * | 2008-04-30 | 2012-06-12 | National Health Research Institutes | Treatment of neurodegenerative disorders with thiourea compounds |
| NZ589764A (en) * | 2008-05-09 | 2012-10-26 | Univ Emory | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
| CA2731097A1 (en) * | 2008-07-15 | 2010-01-21 | Novartis Ag | Organic compounds |
| JP2011529090A (ja) * | 2008-07-28 | 2011-12-01 | 江蘇国華投資有限公司 | アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用 |
| JP2012501307A (ja) * | 2008-09-01 | 2012-01-19 | ノイロサーチ アクティーゼルスカブ | ピペリジン−４−アセトアミド誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのその使用 |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| US9034911B2 (en) | 2008-10-28 | 2015-05-19 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
| EA020548B1 (ru) * | 2008-12-19 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл |
| US8748623B2 (en) | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
| TWI481601B (zh) | 2009-08-21 | 2015-04-21 | Otsuka Pharma Co Ltd | 含氮化合物及藥學組成物 |
| CA2771136A1 (en) | 2009-08-21 | 2011-02-24 | Otsuka Pharmaceutical Co., Ltd. | Process for producing benzo[b][1,4]diazepine-2,4-dione compound |
| MX346393B (es) | 2009-12-17 | 2017-03-17 | Centrexion Therapeutics Corp | Nuevos antagonistas del receptor ccr2 y usos de los mismo. |
| US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| WO2011109679A2 (en) * | 2010-03-05 | 2011-09-09 | Amira Pharmaceuticals, Inc. | Inhibitors of 5-lipoxygenase |
| JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011144501A1 (en) * | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
| EP2576542B1 (en) | 2010-05-25 | 2015-04-22 | Boehringer Ingelheim International GmbH | Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases |
| WO2011151251A1 (en) | 2010-06-01 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New ccr2 antagonists |
| US8779149B2 (en) | 2010-08-23 | 2014-07-15 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| CN102206214B (zh) | 2011-04-07 | 2014-03-12 | 华中科技大学 | 苯并吡喃酮类衍生物及其应用 |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| AR088352A1 (es) * | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| WO2013169964A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US9624197B2 (en) * | 2012-11-27 | 2017-04-18 | Merck Sharp & Dohme Corp. | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
| WO2014137883A1 (en) * | 2013-03-08 | 2014-09-12 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-ether orexin receptor antagonists |
| EP2968304B1 (en) * | 2013-03-14 | 2018-10-10 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
| CN104059046B (zh) * | 2013-03-18 | 2017-02-08 | 江苏恩华药业股份有限公司 | 黄酮类衍生物及其应用 |
| CN104447723A (zh) * | 2014-11-28 | 2015-03-25 | 瑞阳制药有限公司 | 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法 |
| RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
| WO2017004537A1 (en) | 2015-07-02 | 2017-01-05 | Centrexion Therapeutics Corporation | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
| EP3322415A4 (en) | 2015-07-15 | 2019-03-13 | Axovant Sciences GmbH | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE |
| CN106749219A (zh) * | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
| US10464931B2 (en) | 2015-12-28 | 2019-11-05 | Honour (R&D) | Process for the preparation of Quinolin-2(1H)-one derivatives |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN112125896B (zh) * | 2020-09-29 | 2021-10-29 | 湖南省湘中制药有限公司 | 一种抗精神病药依匹哌唑电化学制备方法 |
| CN112079812B (zh) * | 2020-09-29 | 2021-08-06 | 浙江大学 | 哌唑类抗精神病药物关键中间体及其电还原方法 |
| EP4236937B1 (en) * | 2020-10-27 | 2025-07-23 | Arena Pharmaceuticals, Inc. | Pyrimidine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| CN115772175A (zh) * | 2021-09-07 | 2023-03-10 | 中国科学院分子细胞科学卓越创新中心 | 噻吩并环化合物及其制备方法和应用 |
| CN116554145B (zh) * | 2022-01-29 | 2025-06-03 | 江苏恩华药业股份有限公司 | 芳烷基-4-(1h)吲哚基哌嗪衍生物、其制备方法和应用 |
| IL314361B2 (en) | 2022-01-29 | 2025-04-01 | Suven Life Sciences Ltd | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders |
| CN115521298A (zh) * | 2022-05-09 | 2022-12-27 | 江苏慧聚药业股份有限公司 | 依匹哌唑的制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0005828B1 (de) | 1978-06-06 | 1981-03-11 | Hoechst Aktiengesellschaft | Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung |
| JPS5649361A (en) | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US4883795A (en) | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| DK611489A (da) * | 1988-12-08 | 1990-06-09 | Duphar Int Res | Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser |
| WO1991000863A1 (en) | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
| CA2067475C (en) | 1991-05-08 | 2000-10-10 | Yasuo Oshiro | Carbostyril derivatives and their use |
| US5240927A (en) * | 1992-05-19 | 1993-08-31 | Hoechst-Roussel Pharmaceuticals Incorporated | Benzo[β]thiophen-3-yl piperazines as antipsychotic agents |
| DK148292D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Forbindelser |
| US5576321A (en) | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| DK0732332T3 (da) * | 1995-03-17 | 2002-04-15 | Aventis Pharma Inc | Substituerede benzothienylpiperaziner, deres anvendelse som lægemidler og fremgangsmåder til fremstilling deraf |
| FR2740134B1 (fr) | 1995-10-18 | 1998-01-09 | Pf Medicament | Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant |
| EP0934932A4 (en) | 1996-08-22 | 2002-06-26 | Meiji Seika Kaisha | CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM |
| FR2761068B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique |
| NZ516111A (en) | 1999-05-24 | 2003-05-30 | Mitsubishi Pharma Corp | Phenoxypropylamine compounds useful to treat depression |
| AR027133A1 (es) * | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de heteroarilo, su preparacion y uso. |
| AR027134A1 (es) * | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de indol. |
| EP1688412A3 (en) | 2001-02-16 | 2006-08-16 | Aventis Pharmaceuticals, Inc. | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands |
| US6982332B2 (en) | 2001-06-07 | 2006-01-03 | Wayne State University | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity |
| CA2451229C (en) * | 2001-06-29 | 2009-02-10 | H. Lundbeck A/S | Indole derivatives |
| AU2003263413A1 (en) | 2002-09-17 | 2004-04-08 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
| MXPA05002003A (es) | 2002-09-26 | 2005-08-03 | Warner Lambert Co | Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia. |
| GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
-
2006
- 2006-08-30 AR ARP060103780A patent/AR055203A1/es unknown
- 2006-08-30 TW TW095132016A patent/TWI329641B/zh not_active IP Right Cessation
- 2006-08-31 AU AU2006285607A patent/AU2006285607B2/en not_active Ceased
- 2006-08-31 EP EP06797580A patent/EP1919907B9/en not_active Not-in-force
- 2006-08-31 PL PL06797580T patent/PL1919907T3/pl unknown
- 2006-08-31 EP EP10188683A patent/EP2287162B1/en not_active Not-in-force
- 2006-08-31 MX MX2008002736A patent/MX2008002736A/es active IP Right Grant
- 2006-08-31 AT AT06797580T patent/ATE499369T1/de active
- 2006-08-31 CA CA2620688A patent/CA2620688C/en not_active Expired - Fee Related
- 2006-08-31 MY MYPI20080316A patent/MY145670A/en unknown
- 2006-08-31 SG SG200905174-9A patent/SG155180A1/en unknown
- 2006-08-31 AT AT10188671T patent/ATE557021T1/de active
- 2006-08-31 WO PCT/JP2006/317704 patent/WO2007026959A2/en not_active Ceased
- 2006-08-31 CN CN2011104410868A patent/CN102558140A/zh active Pending
- 2006-08-31 AT AT10188688T patent/ATE549330T1/de active
- 2006-08-31 ES ES10188688T patent/ES2382445T3/es active Active
- 2006-08-31 SI SI200630973T patent/SI1919907T1/sl unknown
- 2006-08-31 RU RU2008112224/04A patent/RU2415854C2/ru not_active IP Right Cessation
- 2006-08-31 EP EP10188688A patent/EP2284169B1/en not_active Not-in-force
- 2006-08-31 CN CN2011104414290A patent/CN102850336A/zh active Pending
- 2006-08-31 DK DK06797580.5T patent/DK1919907T5/da active
- 2006-08-31 AT AT10188683T patent/ATE557022T1/de active
- 2006-08-31 PT PT06797580T patent/PT1919907E/pt unknown
- 2006-08-31 CN CN2006800320431A patent/CN101258147B/zh not_active Expired - Fee Related
- 2006-08-31 JP JP2006235401A patent/JP4785677B2/ja not_active Expired - Fee Related
- 2006-08-31 EP EP10188671A patent/EP2287161B1/en not_active Not-in-force
- 2006-08-31 ES ES10188671T patent/ES2383948T3/es active Active
- 2006-08-31 BR BRPI0615140-0A patent/BRPI0615140A2/pt not_active IP Right Cessation
- 2006-08-31 KR KR1020107009007A patent/KR20100063807A/ko not_active Abandoned
- 2006-08-31 DE DE602006020294T patent/DE602006020294D1/de active Active
- 2006-08-31 CN CN2011104423270A patent/CN102702182A/zh active Pending
- 2006-08-31 ES ES10188683T patent/ES2383949T3/es active Active
- 2006-08-31 KR KR1020087004418A patent/KR101008873B1/ko not_active Expired - Fee Related
- 2006-08-31 US US11/991,146 patent/US8071600B2/en not_active Expired - Fee Related
- 2006-08-31 ES ES06797580T patent/ES2362961T3/es active Active
- 2006-08-31 ZA ZA200801888A patent/ZA200801888B/xx unknown
-
2008
- 2008-02-07 IL IL189383A patent/IL189383A/en not_active IP Right Cessation
-
2010
- 2010-02-01 AU AU2010200362A patent/AU2010200362A1/en not_active Ceased
-
2011
- 2011-04-18 CY CY20111100400T patent/CY1111671T1/el unknown
- 2011-10-11 US US13/270,544 patent/US8598162B2/en not_active Expired - Fee Related
-
2013
- 2013-09-20 US US14/032,568 patent/US20140031334A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055203A1 (es) | Derivados de benzotiofeno con propiedades antipsicoticas | |
| RU2405771C2 (ru) | Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 | |
| ES2406089T3 (es) | Pirazolpirimidinas sustituidas | |
| CO5700817A2 (es) | Compuesto pentaciclico heteroaromatico y uso medicinal del mismo | |
| US6503937B1 (en) | Oxobenzofuranylide-dihydroindolone | |
| RS59306B1 (sr) | Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr) | |
| NZ508765A (en) | Beta-carboline derivatives and pharmaceuticals thereof that selectively bind somatostatin receptor subtypes | |
| Rakitin | Recent developments in the synthesis of 1, 2, 5-thiadiazoles and 2, 1, 3-benzothiadiazoles | |
| CA2946702C (en) | Bicyclic or tricyclic heterocyclic compound | |
| IL190780A0 (en) | Heterocyclic substituted aminoazacycles useful as central nervous system agents | |
| Chen et al. | Synthesis of 2-substituted-3-(1 H-indol-3-yl) isoindolin-1-one derivatives in water under catalyst-free conditions | |
| PE20081458A1 (es) | DERIVADOS DE PIRIDO[2,3-b]INDOL COMO INHIBIDORES DE QUINASAS | |
| MX2009006650A (es) | Pirimidinas substituidas que contienen una porcion heteroarilamida o heteroarilfenilo. | |
| AR054191A1 (es) | Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina | |
| Sarkar et al. | Synthesis and photophysics of selective functionalized π-conjugated, blue light emitting, highly fluorescent C7-imidazo indolizine derivatives | |
| Verbitskiy et al. | Assembly of annulated 1, 3-diazapyrenes by consecutive cross-coupling and cyclodehydrogenation of (het) arene moieties | |
| Karpenko et al. | Experimental and theoretical spectroscopic study of thione-thiol tautomerism of new hybrides 1, 3, 4-oxadiazole-2-thion with acridine-9 (10h)-one | |
| ATE515540T1 (de) | Trisazofarbstoffe mit pyrazolylendgruppe und ihre verwendung im farbstrahldruck | |
| Abdel Hamid et al. | Synthesis and fluorescent properties of some Furan‐tagged Thieno [2, 3‐d] pyrimidines and Thieno [2, 3‐d: 4, 5‐d'] dipyrimidines | |
| GB2450812A (en) | Compound, ink process and use | |
| KR890014552A (ko) | 헤테로고리 치환된 5,7-디히드로 피롤로[3,2-f]-벤즈옥사졸-6-온, 이들의 제조방법 및 이들을 함유하는 제약조성물 | |
| Brukstus et al. | A facile synthesis of benzo [4, 5] imidazo [2, 1-b]-pyrimido [5, 4-f][1, 3, 4] thiadiazepines | |
| ATE412038T1 (de) | Tintenstrahltinte | |
| Hassan et al. | Dicyanomethylene compounds and heterocyclization of substituted carbohydrazides | |
| DE602004003061D1 (de) | Magenta metallkomplexazofarbstoffe und tinte sowie ihre verwendung in dem tintenstrahldruck |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |